Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a T-Cell signature unlock the secrets of autoimmune liver disease?

NCT ID NCT07784881

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This study aims to identify the unique molecular signature of immune cells called T cells that mistakenly attack the liver in autoimmune liver diseases like autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. Researchers will analyze blood samples from 220 people with these conditions to understand what makes these self-reactive T cells distinct. The goal is to better understand the underlying mechanisms of these diseases, which could inform future diagnostic or treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could lead to a deeper understanding of autoimmune liver diseases, potentially pointing toward new diagnostic tools or targeted therapies.
What could go wrong
This is an observational study, so it won't directly test a treatment. The findings may not translate into immediate clinical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

220 people

The number who actually took part.

Started

Apr 2021

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Auto-Immune Hepatitis

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient informed consent * AIH with no previous treatment whose diagnosis is validated by at least 2 of the following criteria: * ALT\>2N or IgG\>1.1N * Presence of autoantibodies : ANA (antinuclear), ML (anti-smooth muscle), SLA (anti-soluble liver antigen), LKM1 (anti-endoplasmic reticulum), LC1 (anti-liver cytosol) * Presence of interface hepatitis on biopsy Exclusion Criteria: * HIV positive * HBV infection Positive * HCV serology positive and PCR positive

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune hepatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis Cholangitis, Sclerosing primary biliary cholangitis primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune hepatitis Autoimmune liver disease Primary biliary cholangitis (PBC) Primary sclerosing cholangitis (PSC)

Contacts and locations

Locations

  • Nantes University Hospital

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.